¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå : ¼¼°è »ê¾÷ ºÐ¼®, ±Ô¸ð, Á¡À¯À², ¼ºÀå, µ¿Çâ, ¿¹Ãø(2024-2031³â)
Microbial Fermentation CMO Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2031
»óǰÄÚµå
:
1572931
¸®¼Ä¡»ç
:
Persistence Market Research
¹ßÇàÀÏ
:
2024³â 10¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 210 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
»ùÇà ¿äû ¸ñ·Ï¿¡ Ãß°¡
Persistence Market Research´Â À̹ø¿¡ ¼¼°èÀÇ ¹Ì»ý¹° ¹ßÈ¿ ¼öŹÁ¦Á¶ ±â°ü(CMO) ½ÃÀåÀ» »ó¼¼ÇÏ°Ô Á¶»çÇÑ Á¾ÇÕ º¸°í¼¸¦ ¹ßÇàÇß½À´Ï´Ù. ½ÃÀå ¼ºÀå ÃËÁø¿äÀΡ¤µ¿Ç⡤±âȸ¡¤°úÁ¦ µîÀÇ ÁÖ¿ä ½ÃÀå ¿ªÇÐÀ» öÀúÇÏ°Ô Æò°¡Çϰí, ½ÃÀå ±¸Á¶¿¡ °üÇÑ »ó¼¼ ÀλçÀÌÆ®À» Á¦°øÇϰí ÀÖ½À´Ï´Ù. ÀÌ Á¶»ç ¸®Æ÷Æ®´Â 2024-2031³âÀÇ ¼¼°è ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀåÀÇ ¿¹Ãø ¼ºÀå ±Ëµµ¸¦ ¼³¸íÇÏ´Â µ¶Á¡ µ¥ÀÌÅÍ¿Í Åë°è¸¦ °ÔÀçÇϰí ÀÖ½À´Ï´Ù.
ÁÖ¿ä ÀλçÀÌÆ®
¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå ±Ô¸ð(2024³â) : 38¾ï ´Þ·¯
¿¹Ãø ½ÃÀå ±Ý¾×(2031³â) : 69¾ï ´Þ·¯
¿¹Ãø ¼ºÀå·ü(CAGR 2024-2031³â) : 8.9%
¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå - Á¶»ç ¹üÀ§ :
¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀåÀº Á¦¾à, ½Äǰ ¹× À½·á, ³ó¾÷, »ê¾÷ Á¦Á¶ µî ´Ù¾çÇÑ ºÐ¾ß¿¡¼ Áß¿äÇÑ ¿ªÇÒÀ» Çϰí ÀÖ½À´Ï´Ù. ÀÌ ½ÃÀåÀº ¹ÚÅ׸®¾Æ, È¿¸ð, °õÆÎÀÌ µî ¹Ì»ý¹°À» Ȱ¿ëÇÏ¿© °¡Ä¡ ÀÖ´Â Á¦Ç°À» »ý»êÇÕ´Ï´Ù. Ç×»ýÁ¦, ¹é½Å, È¿¼ÒÀÇ Çʿ伺À¸·Î ÀÎÇØ ¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇÔ¿¡ µû¶ó Á¦¾à»çµéÀº »ý»ê°ú ±Ô¸ð È®´ë¸¦ À§ÇØ CMO¿¡ ÀÇÁ¸Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀåÀÇ ÃËÁø¿äÀÎ:
¼¼°è ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀåÀº ¸¸¼ºÁúȯ Áõ°¡¿Í ÷´Ü Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ ±ä±ÞÇÑ ¼ö¿ä µî ¸î °¡Áö Áß¿äÇÑ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ´ç´¢º´, ¾Ï, ÀÚ°¡¸é¿ªÁúȯ°ú °°Àº Áúº´À¸·Î ÀÎÇØ ¹ÙÀÌ¿ÀÀǾàǰ¿¡ ´ëÇÑ ¼ö¿ä°¡ Áö¼ÓÀûÀ¸·Î Áõ°¡ÇÔ¿¡ µû¶ó ÷´Ü Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ º¯È´Â CMOÀÇ °Á¡ÀÎ À¯¿¬Çϰí È®Àå °¡´ÉÇÑ ¹ßÈ¿ °øÁ¤ÀÇ Á߿伺À» °Á¶Çϰí ÀÖ½À´Ï´Ù.
½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ :
±àÁ¤ÀûÀÎ ¼ºÀå Àü¸Á¿¡µµ ºÒ±¸ÇÏ°í ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀåÀº °ø±Þ¸ÁÀÇ º¹À⼺°ú °ü·ÃµÈ ¹®Á¦¿¡ Á÷¸éÇØ ÀÖ½À´Ï´Ù. °íǰÁú ¿ø·á Á¶´ÞÀÇ ¾î·Á¿ò°ú ¼¶¼¼ÇÑ »ý¹°ÇÐÀû ¹°ÁúÀÇ ¿î¼Û¿¡ ´ëÇÑ ¹°·ù ¹®Á¦°¡ ½ÃÀåÀÇ È¿À²¼ºÀ» Å©°Ô ÀúÇØÇϰí ÀÖ½À´Ï´Ù. ¹ßÈ¿ °øÁ¤¿¡ ÇʼöÀûÀÎ ±âÁúÀÇ °¡¿ë¼º°ú ǰÁúÀÌ ÀÏÁ¤ÇÏÁö ¾ÊÀ¸¸é »ý»ê Áö¿¬°ú ºñ¿ë Áõ°¡·Î À̾îÁ® CMO°¡ ¼ö¿ä Áõ°¡¿¡ ´ëÀÀÇÒ ¼ö ÀÖ´Â ´É·Â¿¡ ¿µÇâÀ» ¹ÌÄ¥ ¼ö ÀÖ½À´Ï´Ù.
½ÃÀå ±âȸ :
¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀåÀº Áö¼Ó°¡´É¼º°ú ģȯ°æ ±â¼ú·Î ÀÎÇØ Å« ¼ºÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù. ±â¾÷Àº Æó±â¹° ¹× ¿¡³ÊÁö ¼Òºñ¸¦ ÃÖ¼ÒÈÇϱâ À§ÇØ ¹ßÈ¿ °øÁ¤À» ÃÖÀûÈÇÏ´Â µî ȯ°æ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» ÁÙÀ̱â À§ÇØ Áö¼Ó°¡´ÉÇÑ ¹æ¹ýÀ» äÅÃÇϰí ÀÖ½À´Ï´Ù. ÀÌ´Â Àü ¼¼°èÀûÀÎ Áö¼Ó°¡´É¼º ¿îµ¿°ú ÀÏÄ¡Çϸç, ȯ°æ Ä£ÈÀû °üÇàÀ» ¿ì¼±½ÃÇÏ´Â CMO¿¡ ¾öû³ ½ÃÀå ±âȸ¸¦ Á¦°øÇÕ´Ï´Ù.
ÀÌ º¸°í¼¿¡¼ ´Ù·é ÁÖ¿ä Áú¹®
¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀåÀÇ ¼¼°è ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀº?
¹ÙÀÌ¿À ±â¼úÀÇ ¹ßÀüÀº ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå °æÀï ±¸µµ¸¦ ¾î¶»°Ô º¯È½Ã۰í Àִ°¡?
¹ÙÀÌ¿ÀÀǾàǰ ºÐ¾ß CMOÀÇ ¾÷¹«¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ±ÔÁ¦ À̽´´Â ¹«¾ùÀΰ¡?
¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷Àº ¾îµð¿¡ ÀÖÀ¸¸ç, °ü·Ã¼ºÀ» À¯ÁöÇϱâ À§ÇØ ¾î¶² Àü·«À» ÃëÇϰí Àִ°¡?
¼¼°è ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå¿¡¼ ¿¹»óµÇ´Â »õ·Î¿î µ¿Çâ°ú Àü¸ÁÀº?
¸ñÂ÷
Á¦1Àå °³¿ä
Á¦2Àå ½ÃÀå °³¿ä
½ÃÀåÀÇ ¹üÀ§¿Í Á¤ÀÇ
½ÃÀå ¿ªÇÐ
ÃËÁø¿äÀÎ
¾ïÁ¦¿äÀÎ
±âȸ
°úÁ¦
ÁÖ¿ä µ¿Çâ
°Å½Ã°æÁ¦ ¿äÀÎ
¼¼°èÀÇ ºÎ¹®º° Àü¸Á
¼¼°èÀÇ GDP ¼ºÀå Àü¸Á
¼¼°èÀÇ ÇコÄɾîºñ ÁöÃâ Àü¸Á
COVID-19ÀÇ ¿µÇ⠺м®
¿¹Ãø ¿äÀÎ - °ü·Ã¼º°ú ¿µÇâ
Á¦3Àå ºÎ°¡°¡Ä¡ ÀλçÀÌÆ®
±ÔÁ¦ »óȲ
¹ë·ùüÀÎ ºÐ¼®
ÁÖ¿ä °Å·¡¿Í ÇÕº´
PESTLE ºÐ¼®
Porter's Five Forces ºÐ¼®
Á¦4Àå ¼¼°èÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯)¿Í Àü³â´ëºñ ¼ºÀå·ü
Àý´ë¾× ±âȸ
½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø
°ú°Å ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, 2024-2031³â
¼¼°èÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : ¹ßÇö ½Ã½ºÅÛ À¯Çü
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®, ¹ßÇö ½Ã½ºÅÛ À¯Çüº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, ¹ßÇö ½Ã½ºÅÛ À¯Çüº°, 2024-2031³â
¼¼±Õ ¹ßÇö ½Ã½ºÅÛ
È¿¸ð ¹ßÇö ½Ã½ºÅÛ
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ¹ßÇö ½Ã½ºÅÛ À¯Çü
¼¼°èÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : »ý¹°Á¦Á¦ À¯Çü
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®, »ý¹°Á¦Á¦ À¯Çüº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, »ý¹°Á¦Á¦ À¯Çüº°, 2024-2031³â
È¿¼Ò
Ç×ü
Çö󽺹̵å DNA
ÀçÁ¶ÇÕ ´Ü¹éÁú
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : »ý¹°Á¦Á¦ À¯Çü
¼¼°èÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : ÃÖÁ¾»ç¿ëÀÚ
¼·Ð/ÁÖ¿ä Á¶»ç °á°ú
°ú°Å ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®, ÃÖÁ¾»ç¿ëÀÚº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, ÃÖÁ¾»ç¿ëÀÚº°, 2024-2031³â
¹ÙÀÌ¿ÀÀǾàǰ ±â¾÷
Çмú¡¤¿¬±¸±â°ü
±âŸ
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : ÃÖÁ¾»ç¿ëÀÚ
Á¦5Àå ¼¼°èÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : Áö¿ª
ÁÖ¿ä ÇÏÀ̶óÀÌÆ®
°ú°Å ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®, Áö¿ªº°, 2019-2023³â
ÇöÀç ½ÃÀå ±Ô¸ð(¹é¸¸ ´Þ·¯) ºÐ¼®°ú ¿¹Ãø, Áö¿ªº°, 2024-2031³â
ºÏ¹Ì
À¯·´
µ¿¾Æ½Ã¾Æ
³²¾Æ½Ã¾Æ¡¤¿À¼¼¾Æ´Ï¾Æ
¶óƾ¾Æ¸Þ¸®Ä«
Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
½ÃÀåÀÇ ¸Å·Â ºÐ¼® : Áö¿ª
Á¦6Àå ºÏ¹ÌÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)
Á¦7Àå À¯·´ÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)
Á¦8Àå µ¿¾Æ½Ã¾ÆÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)
Á¦9Àå ³²¾Æ½Ã¾Æ¡¤¿À¼¼¾Æ´Ï¾ÆÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)
Á¦10Àå ¶óÆ¾¾Æ¸Þ¸®Ä«ÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)
Á¦11Àå Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ ¹Ì»ý¹° ¹ßÈ¿ CMO ½ÃÀå Àü¸Á : ½ÇÀû(2019-2023³â)°ú ¿¹Ãø(2024-2031³â)
Á¦12Àå °æÀï ±¸µµ
½ÃÀå ±¸Á¶
°æÀï °ÝÈ ¸Ê : ½ÃÀ庰
°æÀï ´ë½Ãº¸µå
±â¾÷ °³¿ä(»ó¼¼ - °³¿ä, À繫, Àü·«, ÃÖ±Ù µ¿Çâ)
AbbVie Inc.
BOC Sciences
Eurofins Scientific
FUJIFILM Diosynth Biotechnologies
GSK plc
Lonza Group AG
Sandoz Group AG
WuXi Biologics
Evonik Industries
DSM
Sekisui Diagnostics
AGC Biologics
BIOVECTRA
Avid Bioservices
Á¦13Àå ºÎ·Ï
Á¶»ç ¹æ¹ý
Á¶»çÀÇ ÀüÁ¦Á¶°Ç
µÎÀÚ¾î¿Í ¾à¾î
KSA
¿µ¹® ¸ñÂ÷
Persistence Market Research has recently published a comprehensive report detailing the global microbial fermentation contract manufacturing organization (CMO) market. The report offers a thorough assessment of key market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure. This research publication presents exclusive data and statistics outlining the anticipated growth trajectory of the global microbial fermentation CMO market from 2024 to 2031.
Key Insights:
Microbial Fermentation CMO Market Size (2024E): US$3.8 Bn
Projected Market Value (2031F): US$6.9 Bn
Forecast Growth Rate (CAGR 2024-2031): 8.9%
Microbial Fermentation CMO Market - Report Scope:
The microbial fermentation CMO market plays a critical role across various sectors, including pharmaceuticals, food and beverages, agriculture, and industrial manufacturing. This market leverages microorganisms like bacteria, yeast, and fungi to produce valuable products. As demand for biopharmaceuticals surges, driven by the need for antibiotics, vaccines, and enzymes, pharmaceutical companies increasingly rely on CMOs for production and scale-up.
Market Growth Drivers:
The global microbial fermentation CMO market is propelled by several key factors, including the increasing prevalence of chronic diseases and the urgent need for advanced therapeutic solutions. As the demand for biopharmaceuticals continues to rise, driven by conditions such as diabetes, cancer, and autoimmune disorders, the necessity for advanced therapeutic solutions intensifies. This shift emphasizes the importance of flexible and scalable fermentation processes that CMOs specialize in.
Market Restraints:
Despite the positive growth outlook, the microbial fermentation CMO market faces challenges related to supply chain complexities. Issues in sourcing high-quality raw materials and logistical challenges in transporting sensitive biological materials significantly hinder market efficiency. Inconsistent availability and quality of essential substrates for fermentation processes can lead to production delays and increased costs, impacting the ability of CMOs to meet rising demand.
Market Opportunities:
The microbial fermentation CMO market presents significant growth opportunities driven by sustainability and green technologies. Companies are increasingly adopting sustainable practices to reduce their environmental impact, including optimizing fermentation processes to minimize waste and energy consumption. This aligns with the global sustainability movement, presenting a massive market opportunity for CMOs that prioritize environmentally friendly practices.
Key Questions Answered in the Report:
What are the primary factors driving the growth of the microbial fermentation CMO market globally?
How are advancements in biotechnology reshaping the competitive landscape of the microbial fermentation CMO market?
What regulatory challenges are impacting the operations of CMOs in the biopharmaceutical sector?
Which companies are the key players in the microbial fermentation CMO market, and what strategies are they employing to maintain relevance?
What emerging trends and future prospects are anticipated in the global microbial fermentation CMO market?
Competitive Intelligence and Business Strategy:
Leading players in the global microbial fermentation CMO market, including Lonza, Samsung Biologics, and WuXi Biologics, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies are investing heavily in R&D to develop advanced fermentation technologies and scalable manufacturing solutions catering to diverse therapeutic needs. Collaborations with regulatory agencies, research institutions, and healthcare providers facilitate market access and promote technology adoption.
Key Companies Profiled:
AbbVie Inc.
BOC Sciences
Eurofins Scientific
FUJIFILM Diosynth Biotechnologies
GSK plc
Lonza Group AG
Sandoz Group AG
WuXi Biologics
Evonik Industries
DSM
Sekisui Diagnostics
AGC Biologics
BIOVECTRA
Avid Bioservices
Microbial Fermentation CMO Market Segmentation
By Expression System
Bacterial Expression Systems
Yeast Expression Systems
Others
By Biologics
Enzymes
Antibodies
Plasmid DNA
Recombinant Proteins
Others
By End User
Biopharma Companies
Academic & Research Institutes
Others
By Region
North America
Europe
Asia Pacific
The Middle East and Africa
Latin America
Table of Contents
1. Executive Summary
1.1. Global Microbial Fermentation CMO Market Snapshot, 2024-2031
1.2. Market Opportunity Assessment, 2024-2031, US$ Mn
1.3. Key Market Trends
1.4. Future Market Projections
1.5. Premium Market Insights
1.6. Industry Developments and Key Market Events
1.7. PMR Analysis and Recommendations
2. Market Overview
2.1. Market Scope and Definition
2.2. Market Dynamics
2.2.1. Drivers
2.2.2. Restraints
2.2.3. Opportunity
2.2.4. Challenges
2.2.5. Key Trends
2.3. Macro-Economic Factors
2.3.1. Global Sectorial Outlook
2.3.2. Global GDP Growth Outlook
2.3.3. Global Healthcare Spending Outlook
2.4. COVID-19 Impact Analysis
2.5. Forecast Factors - Relevance and Impact
3. Value Added Insights
3.1. Regulatory Landscape
3.2. Value Chain Analysis
3.3. Key Deals and Mergers
3.4. PESTLE Analysis
3.5. Porter's Five Force Analysis
4. Global Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
4.1. Key Highlights
4.1.1. Market Size (US$ Mn) and Y-o-Y Growth
4.1.2. Absolute $ Opportunity
4.2. Market Size (US$ Mn) Analysis and Forecast
4.2.1. Historical Market Size (US$ Mn) Analysis, 2019-2023
4.2.2. Current Market Size (US$ Mn) Analysis and Forecast, 2024-2031
4.3. Global Microbial Fermentation CMO Market Outlook: Type of Expression Systems
4.3.1. Introduction / Key Findings
4.3.2. Historical Market Size (US$ Mn) Analysis, By Type of Expression Systems, 2019-2023
4.3.3. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
4.3.3.1. Bacterial Expression Systems
4.3.3.2. Yeast Expression Systems
4.3.3.3. Others
4.4. Market Attractiveness Analysis: Type of Expression Systems
4.5. Global Microbial Fermentation CMO Market Outlook: Type of Biologics
4.5.1. Introduction / Key Findings
4.5.2. Historical Market Size (US$ Mn) Analysis, By Type of Biologics, 2019-2023
4.5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
4.5.3.1. Enzymes
4.5.3.2. Antibodies
4.5.3.3. Plasmid DNA
4.5.3.4. Recombinant Proteins
4.5.3.5. Others
4.6. Market Attractiveness Analysis: Type of Biologics
4.7. Global Microbial Fermentation CMO Market Outlook: End User
4.7.1. Introduction / Key Findings
4.7.2. Historical Market Size (US$ Mn) Analysis, By End User, 2019-2023
4.7.3. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
4.7.3.1. Biopharma Companies
4.7.3.2. Academic & Research Institutes
4.7.3.3. Others
4.8. Market Attractiveness Analysis: End User
5. Global Microbial Fermentation CMO Market Outlook: Region
5.1. Key Highlights
5.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
5.3. Current Market Size (US$ Mn) Analysis and Forecast, By Region, 2024-2031
5.3.1. North America
5.3.2. Europe
5.3.3. East Asia
5.3.4. South Asia and Oceania
5.3.5. Latin America
5.3.6. Middle East & Africa
5.4. Market Attractiveness Analysis: Region
6. North America Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
6.1. Key Highlights
6.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
6.2.1. By Country
6.2.2. By Type of Expression Systems
6.2.3. By Type of Biologics
6.2.4. By End User
6.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
6.3.1. U.S.
6.3.2. Canada
6.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
6.4.1. Bacterial Expression Systems
6.4.2. Yeast Expression Systems
6.4.3. Others
6.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
6.5.1. Enzymes
6.5.2. Antibodies
6.5.3. Plasmid DNA
6.5.4. Recombinant Proteins
6.5.5. Others
6.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
6.6.1. Biopharma Companies
6.6.2. Academic & Research Institutes
6.6.3. Others
6.7. Market Attractiveness Analysis
7. Europe Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
7.1. Key Highlights
7.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
7.2.1. By Country
7.2.2. By Type of Expression Systems
7.2.3. By Type of Biologics
7.2.4. By End User
7.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
7.3.1. Germany
7.3.2. France
7.3.3. U.K.
7.3.4. Italy
7.3.5. Spain
7.3.6. Russia
7.3.7. Turkiye
7.3.8. Rest of Europe
7.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
7.4.1. Bacterial Expression Systems
7.4.2. Yeast Expression Systems
7.4.3. Others
7.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
7.5.1. Enzymes
7.5.2. Antibodies
7.5.3. Plasmid DNA
7.5.4. Recombinant Proteins
7.5.5. Others
7.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
7.6.1. Biopharma Companies
7.6.2. Academic & Research Institutes
7.6.3. Others
7.7. Market Attractiveness Analysis
8. East Asia Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
8.1. Key Highlights
8.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
8.2.1. By Country
8.2.2. By Type of Expression Systems
8.2.3. By Type of Biologics
8.2.4. By End User
8.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
8.3.1. China
8.3.2. Japan
8.3.3. South Korea
8.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
8.4.1. Bacterial Expression Systems
8.4.2. Yeast Expression Systems
8.4.3. Others
8.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
8.5.1. Enzymes
8.5.2. Antibodies
8.5.3. Plasmid DNA
8.5.4. Recombinant Proteins
8.5.5. Others
8.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
8.6.1. Biopharma Companies
8.6.2. Academic & Research Institutes
8.6.3. Others
8.7. Market Attractiveness Analysis
9. South Asia & Oceania Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
9.1. Key Highlights
9.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
9.2.1. By Country
9.2.2. By Type of Expression Systems
9.2.3. By Type of Biologics
9.2.4. By End User
9.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
9.3.1. India
9.3.2. Southeast Asia
9.3.3. ANZ
9.3.4. Rest of South Asia & Oceania
9.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
9.4.1. Bacterial Expression Systems
9.4.2. Yeast Expression Systems
9.4.3. Others
9.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
9.5.1. Enzymes
9.5.2. Antibodies
9.5.3. Plasmid DNA
9.5.4. Recombinant Proteins
9.5.5. Others
9.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
9.6.1. Biopharma Companies
9.6.2. Academic & Research Institutes
9.6.3. Others
9.7. Market Attractiveness Analysis
10. Latin America Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
10.1. Key Highlights
10.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
10.2.1. By Country
10.2.2. By Type of Expression Systems
10.2.3. By Type of Biologics
10.2.4. By End User
10.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
10.3.1. Brazil
10.3.2. Mexico
10.3.3. Rest of Latin America
10.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
10.4.1. Bacterial Expression Systems
10.4.2. Yeast Expression Systems
10.4.3. Others
10.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
10.5.1. Enzymes
10.5.2. Antibodies
10.5.3. Plasmid DNA
10.5.4. Recombinant Proteins
10.5.5. Others
10.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
10.6.1. Biopharma Companies
10.6.2. Academic & Research Institutes
10.6.3. Others
10.7. Market Attractiveness Analysis
11. Middle East & Africa Microbial Fermentation CMO Market Outlook: Historical (2019-2023) and Forecast (2024-2031)
11.1. Key Highlights
11.2. Historical Market Size (US$ Mn) Analysis, By Market, 2019-2023
11.2.1. By Country
11.2.2. By Type of Expression Systems
11.2.3. By Type of Biologics
11.2.4. By End User
11.3. Current Market Size (US$ Mn) Analysis and Forecast, By Country, 2024-2031
11.3.1. GCC Countries
11.3.2. Egypt
11.3.3. South Africa
11.3.4. Northern Africa
11.3.5. Rest of Middle East & Africa
11.4. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Expression Systems, 2024-2031
11.4.1. Bacterial Expression Systems
11.4.2. Yeast Expression Systems
11.4.3. Others
11.5. Current Market Size (US$ Mn) Analysis and Forecast, By Type of Biologics, 2024-2031
11.5.1. Enzymes
11.5.2. Antibodies
11.5.3. Plasmid DNA
11.5.4. Recombinant Proteins
11.5.5. Others
11.6. Current Market Size (US$ Mn) Analysis and Forecast, By End User, 2024-2031
11.6.1. Biopharma Companies
11.6.2. Academic & Research Institutes
11.6.3. Others
11.7. Market Attractiveness Analysis
12. Competition Landscape
12.1. Market Structure
12.1.1. Competition Intensity Mapping By Market
12.1.2. Competition Dashboard
12.2. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
12.2.1. AbbVie Inc.
12.2.1.1. Overview
12.2.1.2. Segments and Products
12.2.1.3. Key Financials
12.2.1.4. Market Developments
12.2.1.5. Market Strategy
12.2.2. BOC Sciences
12.2.2.1. Overview
12.2.2.2. Segments and Products
12.2.2.3. Key Financials
12.2.2.4. Market Developments
12.2.2.5. Market Strategy
12.2.3. Eurofins Scientific
12.2.3.1. Overview
12.2.3.2. Segments and Products
12.2.3.3. Key Financials
12.2.3.4. Market Developments
12.2.3.5. Market Strategy
12.2.4. FUJIFILM Diosynth Biotechnologies
12.2.4.1. Overview
12.2.4.2. Segments and Products
12.2.4.3. Key Financials
12.2.4.4. Market Developments
12.2.4.5. Market Strategy
12.2.5. GSK plc
12.2.5.1. Overview
12.2.5.2. Segments and Products
12.2.5.3. Key Financials
12.2.5.4. Market Developments
12.2.5.5. Market Strategy
12.2.6. Lonza Group AG
12.2.6.1. Overview
12.2.6.2. Segments and Products
12.2.6.3. Key Financials
12.2.6.4. Market Developments
12.2.6.5. Market Strategy
12.2.7. Sandoz Group AG
12.2.7.1. Overview
12.2.7.2. Segments and Products
12.2.7.3. Key Financials
12.2.7.4. Market Developments
12.2.7.5. Market Strategy
12.2.8. WuXi Biologics
12.2.8.1. Overview
12.2.8.2. Segments and Products
12.2.8.3. Key Financials
12.2.8.4. Market Developments
12.2.8.5. Market Strategy
12.2.9. Evonik Industries
12.2.9.1. Overview
12.2.9.2. Segments and Products
12.2.9.3. Key Financials
12.2.9.4. Market Developments
12.2.9.5. Market Strategy
12.2.10. DSM
12.2.10.1. Overview
12.2.10.2. Segments and Products
12.2.10.3. Key Financials
12.2.10.4. Market Developments
12.2.10.5. Market Strategy
12.2.11. Sekisui Diagnostics
12.2.11.1. Overview
12.2.11.2. Segments and Products
12.2.11.3. Key Financials
12.2.11.4. Market Developments
12.2.11.5. Market Strategy
12.2.12. AGC Biologics
12.2.12.1. Overview
12.2.12.2. Segments and Products
12.2.12.3. Key Financials
12.2.12.4. Market Developments
12.2.12.5. Market Strategy
12.2.13. BIOVECTRA
12.2.13.1. Overview
12.2.13.2. Segments and Products
12.2.13.3. Key Financials
12.2.13.4. Market Developments
12.2.13.5. Market Strategy
12.2.14. Avid Bioservices
12.2.14.1. Overview
12.2.14.2. Segments and Products
12.2.14.3. Key Financials
12.2.14.4. Market Developments
12.2.14.5. Market Strategy
13. Appendix
13.1. Research Methodology
13.2. Research Assumptions
13.3. Acronyms and Abbreviations
°ü·ÃÀÚ·á